OncoMatch/Clinical Trials/NCT06026319
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Is NCT06026319 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including CD79b-19 CAR T cells and Cyclophosphamide for non-hodgkin lymphoma.
Treatment: CD79b-19 CAR T cells · Cyclophosphamide · Fludarabine — This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: * CD79b-19 CAR T cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy
R/R disease after 2 or more prior lines of systemic therapy
Must have received: systemic therapy
R/R disease after 2 or more prior lines of systemic therapy
Must have received: systemic therapy
R/R disease after 2 or more prior lines of therapy
Must have received: autologous stem cell transplant
Relapsed following autologous SCT
Must have received: anthracycline or bendamustine-containing chemotherapy
Prior therapy must include: Anthracycline or bendamustine-containing chemotherapy
Must have received: anti-CD20 monoclonal antibody therapy
Prior therapy must include: Anti-CD20 monoclonal antibody therapy
Must have received: BTK inhibitor
Prior therapy must include: BTKi therapy (progression does not have to be documented on BTKi)
Cannot have received: investigational cellular therapy
Treatment with an any investigational cellular therapy within 8 weeks prior to apheresis
Cannot have received: systemic anti-cancer therapy
Exception: excluding steroids (prednisone) at or below physiologic dosing (5mg)
Any systemic anti-cancer therapy within 1 weeks or 5 half-lives of leukapheresis, whichever is shortest, excluding steroids (prednisone) at or below physiologic dosing (5mg)
Cannot have received: bispecific T cell engager
No bispecific T cell engagers within 6 months of leukapheresis
Cannot have received: alkylating agent (bendamustine)
No bendamustime within 6 months of leukapheresis
Cannot have received: CD19-directed cellular therapy
Prior CD19-directed cellular therapy
Lab requirements
Blood counts
ALC > 100 cells/ul within one week of apheresis; ANC >1000 cells/mm3 without growth factor support; untransfused platelet count >50,000 mm3
Kidney function
creatinine clearance >60 ml/min using the Cockcroft-Gault formula
Liver function
AST and ALT < 2.5 × ULN and direct bilirubin < 1.5 × ULN
Cardiac function
Left ventricular ejection fraction > 40%
Adequate absolute lymphocyte count (ALC > 100 cells/ul) within one week of apheresis. Adequate bone marrow function defined by absolute neutrophil count (ANC) >1000 cells/mm3 without growth factor support (filgrastim within 7 days or pegfilgrastim within 14 days) and untransfused platelet count >50,000 mm3. Left ventricular ejection fraction > 40%. Adequate hepatic function defined by aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 × upper limit of normal (ULN) and direct bilirubin < 1.5 × ULN. Adequate renal function defined by creatinine clearance >60 ml/min using the Cockcroft-Gault formula.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify